GSK to advance mRNA flu vaccine to late-stage trial

FILE PHOTO: GSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022.

FILE PHOTO: GSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. (REUTERS/Dado Ruvic/Illustration//File Photo)


1 photo
Save Story

Estimated read time: Less than a minute

(Corrects paragraph 4 to clarify that GSK plans to ​start more than 20, not 25, late-stage trials in 2026)

Sept 1 (Reuters) - GSK said on ‌Tuesday it will advance its mRNA-based seasonal influenza vaccine candidate ⁠to a late-stage ​trial after mid-stage data ⁠showed it generated stronger immune responses ‌than currently approved ‌standard- and high-dose shots in younger and ⁠older adults.

The British ⁠drugmaker said it would be the first late-stage trial of an mRNA flu vaccine designed to target two key surface proteins, haemagglutinin and neuraminidase, an approach GSK said ‌could improve protection and ​reduce transmission.

In August, Moderna had won U.S. approval for its mFlusiva, the first mRNA-based vaccine for seasonal flu, for people aged 50 and older.

The move comes as part of GSK's plans to start more than ​20 late-stage studies by the end of ‌2026, following a ‌portfolio ⁠review by CEO Luke Miels aimed at speeding up drug development ahead of looming patent cliffs.

GSK intends to begin the late-stage trial ‌for the mRNA ​flu vaccine candidate this ‌month.

(Reporting by Raechel ⁠Thankam ​Job in Bengaluru; Editing by Sherry Jacob-Phillips and Sonia ​Cheema)

Photos

Most recent Lifestyle stories

Related topics

KSL.com Beyond Business
KSL.com Beyond Series

KSL Weather Forecast

KSL Weather Forecast
Play button